Vol. 2 No. 4 (2022)
Health Technology Reviews

Radioiodine Resensitization for Radioiodine-Refractory Metastatic Differentiated Thyroid Cancer

Published April 14, 2022

Key Messages

  • Evidence of radioiodine resensitization was reported in 4 single-arm clinical trials and 3 uncontrolled retrospective cohort studies, which included between 3 and 20 patients. Over half of patients in these 7 studies demonstrated increased radioiodine avidity after resensitization treatment.
  • Where reported, at least half of radioiodine retreated patients remained progression free and/or had not initiated a new treatment by the end of study follow-up.
  • Adverse events associated with radioiodine resensitization therapies were typically mild, with skin-related adverse events being most common.
  • No studies comparing outcomes of radioiodine resensitization therapies against lenvatinib or to no treatment were identified.
  • No evidence on the cost-effectiveness of radioiodine resensitization therapy was found.